Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients.
Fiche du document
9 août 2019
- doi: 10.1038/s41408-019-0223-7
- issn: 2044-5385
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41408-019-0223-7
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31399557
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2044-5385
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E6110C1C36FA5
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Standard of value Older persons Older adults Seniors (Older people) Elderly people Old people Senior citizens Aging people AgedCiter ce document
T. Silzle et al., « Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. », Serveur académique Lausannois, ID : 10.1038/s41408-019-0223-7
Métriques
Partage / Export
Résumé
Lymphopenia is associated with an increased mortality in several medical conditions. Its prognostic impact in myelodysplastic syndromes (MDS) is less well studied. Hence, we analyzed 1023 patients from the Düsseldorf MDS-registry with regard to the absolute lymphocyte count (ALC) at diagnosis. An ALC below the median of the population (1.2 × 10 9 /l) was associated with lower counts of neutrophils (median 1.35 vs. 1.92 × 10 9 /l, p < 0.001) and platelets (median 100 vs. 138 × 10 9 /l, p < 0.001) and with a significant lower overall survival in univariate analysis (whole cohort: median 36 vs. 46 months, p = 0.016; 721 patients without hematopoietic stem cell transplantation or induction chemotherapy: median 36 vs. 56 months, p = 0.001). For low-risk MDS according to IPSS-R, an ALC < 1.2 × 10 9 /l was of additional prognostic value in a multivariate Cox regression model together with age (< or ≥65 years) and LDH (< or ≥normal value of 240 U/l; HR 1.46, 95% CI: 1.03-2.08, p = 0.033). These data support the hypothesis of subtle but clinical relevant changes of the adaptive immune system in MDS. Further studies are necessary to identify the ALC cut-off best suitable for prognostication and the mechanisms responsible for the impairment of lymphoid homeostasis in MDS.